Mag­ic mush­rooms and 'toad ven­om' get this British biotech an over­sub­scribed Se­ries B

A new psy­che­delics play­er burst on­to the scene Mon­day with a hefty Se­ries B, aim­ing to re­fash­ion two well-known drugs in­to ther­a­pies for crip­pling headaches …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER